Convergence Pharmaceuticals Announces Start of Phase II Study for CNV1014802 for Trigeminal Neuralgia

21-Mar-2012 - Convergence Pharmaceuticals Limited announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started. CNV1014802 is novel small molecule, state-dependent sodium channel blocker that exhibits potency and selectivity ...

Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944

Phase I single dose study data demonstrate ideal pharmacokinetic profile and excellent safety and tolerability

22-Nov-2011 - Convergence Pharmaceuticals Limited announced that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.The trial is a randomised, placebo controlled Phase I study to investigate the ...

Convergence Pharmaceuticals Announces Phase I Trial Start of CNV2197944 for Chronic Pain

14-Apr-2011 - Convergence Pharmaceuticals Limited announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun.The trial is a randomised, placebo controlled Phase I study to ...

Convergence Pharmaceuticals and Selcia Announce Drug Discovery Collaboration Around Chronic Pain

23-Nov-2010 - Convergence Pharmaceuticals Limited and Selcia Limited announced that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain. Under the terms of the agreement, Convergence Pharmaceuticals will apply its ion ...